Semaglutide, a glucagon-like peptide (GLP)-1 agonist developed by Novo Nordisk, has demonstrated non-inferiority in cardiovascular (CV) risk, in fact, a 26% reduced composite risk of CV death, non-fatal myocardial infarction and non-fatal stroke, as compared to placebo in a cohort of >3,000 patie...